<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yin A</submitter><funding>Shenzhen Science and Technology Innovation Program</funding><funding>President Foundation of The Third Affiliated Hospital of Southern Medical University</funding><funding>National Natural Science Foundation of China</funding><pagination>97</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12822124</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Preeclampsia (PE) remains a leading cause of maternal and fetal mortality, necessitating reliable first-trimester biomarkers for early identification and pathogenesis elucidation. This study aimed to evaluate the predictive performance of first-trimester serum CA125 for the PE development and to examine their longitudinal associations with blood pressure trajectories during pregnancy.&lt;h4>Methods&lt;/h4>A nested case-control study was conducted within the prospective BiCoS cohort, including 70 PE cases and 70 matched controls. Serum CA125 levels were measured at 12.26 ± 0.44 weeks of gestation and compared using independent t-tests. Logistic regression models were built to assess the predictive performance of CA125 alone, clinical factors, and their combination. Model discri</pubmed_abstract><journal>Journal of translational medicine</journal><pubmed_title>Increased first-trimester CA125 levels associated with the development of preeclampsia.</pubmed_title><pmcid>PMC12822124</pmcid><funding_grant_id>JCYJ20220818103607015</funding_grant_id><funding_grant_id>JCYJ20220818103608017</funding_grant_id><funding_grant_id>YQ202410</funding_grant_id><funding_grant_id>72374227</funding_grant_id><pubmed_authors>Zeng C</pubmed_authors><pubmed_authors>Liu K</pubmed_authors><pubmed_authors>Wu L</pubmed_authors><pubmed_authors>Guan X</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Yin A</pubmed_authors><pubmed_authors>Niu J</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Wu X</pubmed_authors><pubmed_authors>Huang P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Increased first-trimester CA125 levels associated with the development of preeclampsia.</name><description>&lt;h4>Background&lt;/h4>Preeclampsia (PE) remains a leading cause of maternal and fetal mortality, necessitating reliable first-trimester biomarkers for early identification and pathogenesis elucidation. This study aimed to evaluate the predictive performance of first-trimester serum CA125 for the PE development and to examine their longitudinal associations with blood pressure trajectories during pregnancy.&lt;h4>Methods&lt;/h4>A nested case-control study was conducted within the prospective BiCoS cohort, including 70 PE cases and 70 matched controls. Serum CA125 levels were measured at 12.26 ± 0.44 weeks of gestation and compared using independent t-tests. Logistic regression models were built to assess the predictive performance of CA125 alone, clinical factors, and their combination. Model discri</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T18:11:41.092Z</modification><creation>2026-06-04T03:11:57.959Z</creation></dates><accession>S-EPMC12822124</accession><cross_references><pubmed>41402871</pubmed><doi>10.1186/s12967-025-07565-1</doi></cross_references></HashMap>